Clinical Trial Update: Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers [Phase 2]

View source ↗

Summary

A Phase 2 trial of nivolumab in patients with recurrent select rare CNS cancers (medulloblastoma, ependymoma, pineal region tumors, choroid plexus tumors, and a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Meningioma
• Choroid Plexus Tumors
• Ependymoma
• Malignant Meningioma
• Medulloblastoma
• Pineal Region Tumors

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Medulloblastoma, Ependymoma | Phase 2 | Status: COMPLETED